Over 178.6 million PCR tests have been conducted in the country so far
A three-dose course of AstraZeneca's Covid-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
The study, yet to be published in a peer-reviewed medical journal, showed antibody levels against Omicron after the booster shot were higher than antibodies in people who had been infected with and recovered naturally from Covid-19.
After a three-dose course of the vaccine, neutralising levels against Omicron were similar to those against the virus's Delta variant after two doses, the company added.
The Anglo-Swedish drugmaker said researchers at Oxford University who carried out the study were independent from those who worked on the vaccine, Vaxzevria, with AstraZeneca.
Over 178.6 million PCR tests have been conducted in the country so far
It will last for four weeks if 10 or more passengers test positive
Over 178.4 million PCR tests have been conducted in the country so far
Omicron variant is highly contagious and can even infect vaccinated/infected people, say experts
Doctors explain how some people can come into contact with a positive case without getting the virus themselves
Globally, cases decreased by nine per cent between July 25 and 31, as compared to the previous week
Over 178.2 million PCR tests have been conducted in the country so far
Total active cases stand at 18,841